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ABSTRACT
The EGFR inhibitor cetuximab is approved for the treatment of colorectal cancer. 
However, both innate and acquired resistance mechanisms, including compensatory 
feedback loops, limit its efficacy. Nevertheless, the emergence of these feedback loops 
has remained largely unexplored to date. Here, we showed feedback upregulation 
of HER3 and induction of HER3 phosphorylation after cetuximab treatment in colon 
cancer cells. We also showed that this upregulation occurs, at least partly, through 
AKT inhibition. Together with this, we observed increased HER2:HER3 dimerization 
upon cetuximab treatment. Interestingly, lapatinib, a dual EGFR and HER2 tyrosine 
kinase inhibitor, blocked the increase of cetuximab-induced HER3 phosphorylation. 
Additionally, we showed that upon HER3 knockdown, cetuximab combined with 
lapatinib was able to decrease cell viability compared to HER3 expressing cells. These 
results suggest the existence of a cetuximab-induced feedback HER3 activation that 
could potentially result in reduced cetuximab efficacy in colorectal cancer patients. 
Taken together, we provide evidence of the limited effectiveness of cetuximab 
monotherapy compared to rational combinations.
INTRODUCTION
The development of targeted anti-cancer agents has 
revolutionized cancer therapy during the last decades. For 
the treatment of colorectal cancer, antibodies targeting the 
epidermal growth factor receptor (EGFR) like cetuximab 
and panitumumab were the first molecularly targeted 
therapeutics to enter the clinical arena [1–3] and they are 
approved as first line treatment for RAS wild-type non-
resectable metastatic colorectal cancer [4–7].
Although responses in an unselected patient 
population were dismal, the development of positive and 
negative predictive biomarkers has led to significantly 
improved patient selection and has resulted in increased 
clinical benefit [8]. While the use of positive predicting 
factors indicating EGFR activation such as EGFR ligand 
expression still warrants prospective validation [9–11], 
the use of negative predictive oncogenic mutations in 
KRAS, BRAF, NRAS and PIK3CA exon 20 as stratification 
factors resulted in nearly a doubling of the response 
rate to 41% of quadruple wild-type tumors in the first 
line setting [12]. Although they are prevalent in a lower 
proportion of tumors, additional gene amplifications of 
HER2 and MET, among other alterations, were previously 
linked to cetuximab resistance [13, 14]. Recently, HER2, 
EGFR, PDGFRA and MAP2K1 mutations and FGFR1 
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amplifications have been identified as plausible innate 
resistance mechanisms to EGFR targeted therapy in 
colorectal cancer [15], as well as ALK, FGFR2, NTRK1/2 
and RET kinase addition [16].
Clinically, when treated with cetuximab, KRAS 
wild-type colorectal cancers experience on average a 
tumor decrease of only 41% after 24 weeks of treatment, 
leaving a significant tumor mass that could potentially 
develop additional genetic variant alleles associated with 
resistance. This includes EGFR acquired ectodomain 
mutations [17] and KRAS mutations [18, 19] among 
others. These reports advocate the need for therapeutic 
regimens achieving superior tumor kill. These could not 
only improve outcome through larger tumor shrinkage, 
but potentially prevent or delay the emergence of acquired 
resistance and disease progression.
From a biological standpoint, a body of evidence 
across tumor types suggests that antibodies targeting ErbB 
family members mainly function by blocking downstream 
signaling, which are prone to be compensated for by 
parallel signaling. Several compensatory feedback loops 
have been recently identified in the context of BRAF 
inhibitors [20, 21], phosphatidylinositol 3-kinase (PI3K)/
AKT inhibitors [22] and MEK inhibitors [23] among 
others, leading to acquired drug resistance. This diverse 
array of resistance mechanisms seems to converge on 
feedback activation of the PI3K/AKT and the mitogen-
activated protein kinase (MAPK)/extracellular-signal-
regulated kinase (ERK) pathways, ultimately priming 
cancer cells for resistance [24]. Although ErbB inhibitors 
were the first targeted agents developed for the treatment 
of colorectal cancer, the emergence of these feedback 
loops has remained largely unexplored to date in the 
context of these drugs. 
In this study, we aimed to determine whether 
feedback signaling induced by EGFR inhibitors could 
contribute to a decreased efficacy of EGFR inhibitors in 
colon cancer cells. Here, we showed that upon cetuximab 
treatment feedback induction of HER3 phosphorylation 
occurs, which is at least partly a result of AKT inhibition. 
This is coupled with a dimerization shift towards 
HER2:HER3 heterodimers. We also provided evidence 
that the dual EGFR/HER2 inhibitor lapatinib can prevent 
the cetuximab-induced HER3 phosphorylation and 
decrease cell viability.
RESULTS
Feedback induction of HER3 phosphorylation 
occurs after EGFR inhibition with cetuximab 
Several reports have shown feedback activation 
of Receptor Tyrosine Kinases (RTK) upon inhibition of 
different components of the EGFR pathway [20–23]. 
Here, we wanted to identify RTKs that were potentially 
activated during treatment with the monoclonal antibody 
EGFR inhibitor cetuximab in previously identified 
intermediate cetuximab-sensitive KRAS and BRAF 
wild-type colon cancer cell lines. For this purpose, we 
utilized phosphorylated RTK arrays with LIM1215 and 
HCA7 cells (Figure 1A) [16, 18, 25]. As expected, EGFR 
phosphorylation was found significantly inhibited during 
24h cetuximab treatment compared with control treatment 
in both cell lines. Additionally, a clear induction of HER3 
phosphorylation was observed upon treatment, also in both 
cell lines.
We next assessed whether the observed cetuximab-
induced feedback activation of HER3 was time-dependent 
and whether components downstream of EGFR were also 
altered. We hypothesized that cetuximab sensitivity relies 
mainly on the combined inhibition of the PI3K/AKT and 
MAPK/ERK signaling pathways. In order to identify 
potential compensatory activation of these pathways, 
we performed a temporal analysis of the LIM1215 cell 
line treated with cetuximab. Western blotting analysis in 
LIM1215 cells revealed that after initial inhibition of ERK 
and AKT phosphorylation, rebound activation of ERK 
occurred from 10h onwards (Figure 1C). Concurrent with 
the initial inhibition of ERK and AKT phosphorylation 
after 6h cetuximab treatment, HER3 protein levels 
increased (Figure 1C). This was coupled with a parallel 
activation of HER3 at one of its 6 PI3K p85 binding sites, 
Tyr1289, which becomes more evident after prolonged 
cetuximab treatment (Figure 1C and 1D). We confirmed 
these results in an additional cell line, HCA7 (Figure 1C 
and 1D). Together, this suggests that, upon cetuximab 
treatment, feedback HER3 activation may occur, which 
could potentially be associated with ERK and AKT 
inhibition.
AKT inhibition drives HER3 compensatory 
feedback upregulation
Subsequently, we investigated which mechanisms 
downstream of EGFR could result in feedback activation 
of HER3 upon cetuximab treatment. Multiple reports in 
other cancer types indicate that feedback induction of 
RTKs occurs through relief of negative feedback signaling, 
such as AKT-regulated, FOXO-mediated HER2 and HER3 
transcription [26, 27]. First, we assessed if inhibiting 
EGFR would also result in HER3 mRNA upregulation 
as a result of negative feedback signaling disruption. To 
test this, we compared HER3 mRNA levels in LIM1215 
and HCA7 cells treated with different EGFR inhibitors 
including cetuximab, the EGFR tyrosine kinase inhibitor 
gefitinib and the dual EGFR and HER2 tyrosine kinase 
inhibitor lapatinib. Here, we observed that all three drugs 
induced a significant compensatory mRNA upregulation 
of HER3 within 24h (Figure 2A). Concomitant to this, we 
also observed an increase in the HER3 ligand heregulin 
(NRG1) mRNA levels after cetuximab, gefitinib and 
lapatinib treatments (Figure 2B). Next, we investigated 
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if the observed mRNA upregulation of HER3 is due to 
relief of negative feedback exercised by AKT, as described 
in other cancer types. For this purpose, we performed 
transient overexpression of myristoylated AKT, an AKT 
constitutively active mutant construct [28]. Overexpression 
of myristoylated AKT in LIM1215 cells repressed HER3 
transcription by nearly 2-fold in basal conditions, and 
was able to significantly prevent the transcriptional 
changes in HER3 induced by cetuximab in these cells 
(Figure 2C). This was also confirmed in HCA7 cells 
(Figure 2C). These data are in line with previous reports 
in the context of breast cancer [26] and suggest that AKT 
signaling downstream of EGFR represses the transcription 
of HER3 in basal conditions. Consequently, EGFR 
inhibition would block AKT and thus allow upregulation 
of HER3 mRNA. This was further supported by western 
blotting temporal analyses in LIM1215 and HCA7 cells 
where we showed that inhibiting PI3K, which is situated 
upstream of AKT, with GDC-0941 leads to induction of 
HER3 phosphorylation (Figure 2D). Next, we wanted to 
investigate if the MAPK/ERK signaling pathway also 
contributes to the observed HER3 compensatory feedback 
upregulation. To test this, we performed a time course of 
inhibition of the downstream modulator of the MAPK/
ERK signaling pathway MEK with the tyrosine kinase 
inhibitor trametinib. Here, we showed that blocking the 
MAPK/ERK pathway with trametinib does not lead to 
HER3 phosphorylation induction (Figure 2E). Taken 
together, these results suggest that feedback activation of 
HER3 occurs, at least partly, through AKT inhibition.
Cetuximab induces a dimerization shift towards 
HER2:HER3 heterodimers
Our results showed that feedback HER3 activation 
occurs in LIM1215 and HCA7 colon cancer cells upon 
cetuximab treatment (Figure 1). However, HER3 has an 
impaired kinase activity and requires other partners to 
gain signaling capacity [29]. ErbB receptors cannot only 
form homodimers but also heterodimers with other family 
members. Hence, we explored whether the cetuximab-
induced HER3 phosphorylation could be attributed to 
increased dimerization between ErbB family members. 
To this end, we utilized a highly sensitive proximity-
mediated immunoassay, Collaborative Enzyme Enhanced 
Reactive-immunoassay (CEER) to quantify EGFR:HER2, 
Figure 1: Feedback induction of HER3 phosphorylation after 24h EGFR inhibition with cetuximab. (A) LIM1215 and 
HCA7 cells were treated for 24h with cetuximab (50 µg/mL) or control-treated with DMSO and phosphorylation of a set of RTKs was 
assessed with RTK arrays as described in the Materials and Methods section. (B) RTK arrays quantification. (C) LIM1215 and HCA7 
cells were treated with cetuximab (50 µg/mL) for different time points. Protein levels were detected by western blotting as described in the 
Materials and Methods section. (D) Western blotting quantification of P-HER3/HER3.
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EGFR:HER3 and HER2:HER3 heterodimer levels, 
HER3:PI3K p85 binding and receptor phosphorylation 
in a multiplexed array format using LIM1215 cell lysates 
[30]. These exploratory experiments showed that EGFR 
phosphorylation was clearly inhibited upon 24h of 
cetuximab treatment (Figure 3A), in line with our previous 
RTK array result (Figure 1A and 1B). Moreover, we 
observed a simultaneous 5.4-fold induction of HER2:HER3 
dimers, which was associated with a 5-fold increase in 
HER3:PI3K p85 binding and a 1.3-fold decrease in EGFR 
protein levels (Figure 3A). Additionally, our exploratory 
experiments showed a decrease in HER2 phosphorylation 
and an increase in HER3 phosphorylation after cetuximab 
treatment (Supplementary Figure S1), in agreement 
with our RTK array result (Figure 1A and 1B). These 
data provide more evidence concerning feedback HER3 
activation upon cetuximab treatment suggested by RTK 
arrays and western blotting (Figure 1). Moreover, they 
advocate that heterodimerization between HER2 and HER3 
is increased in LIM1215 cells upon cetuximab treatment.
Next, we were interested in confirming the existence 
of HER2:HER3 dimers upon cetuximab treatment 
previously determined by CEER exploratory experiments 
in LIM1215 cells. We utilized a validated, FFPE-
compatible fluorescence lifetime imaging microscopy 
(FLIM)-based assay [31–35], which is an accepted 
gold standard technique for measuring protein-protein 
interactions typically within the < 10 nm range (between 
the centres of the donor and acceptor fluorophores, that 
are directly conjugated to the antibodies, see Materials 
and Methods section), to quantify the in situ interaction 
between HER2 and HER3 in LIM1215 cells. We found 
increased HER2:HER3 dimerization after cetuximab 
treatment in LIM1215 cells (Figure 3B), as previously 
identified by CEER method (Figure 3A). The pseudocolor 
lifetime map for cells treated with cetuximab shows 
a decrease in fluorescence lifetime (expressed in ns) 
compared to untreated cells, which represents energy 
transfer from the donor to acceptor fluorophore due to 
the nanoscale proximity of both fluorophores. FRET 
efficiency, which is the readout of the fraction of HER3 
bound to HER2, was significantly increased upon 
cetuximab treatment compared to control treatment. 
Taken together, these data show induction of HER2:HER3 
dimers after cetuximab treatment in LIM1215 cells by 
means of both CEER and FRET/FLIM techniques.
Figure 2: HER3 mRNA induction by cetuximab is blocked by AKT overexpression. (A and B). LIM1215 and HCA7 cells 
were treated with cetuximab (50 µg/mL), gefitinib (1 µM), lapatinib (1 µM) or control-treated with DMSO for 24h (n = 3) and HER3 and 
NRG1 expression were measured by qPCR as described in the Materials and Methods section. Student’s t-test significance: *p < 0.05, 
**p < 0.01, ***p < 0.001. (C) Transient overexpression of the AKT constitutively active mutant myristoylated AKT (myr-AKT) in LIM1215 
and HCA7 cells. Cells were treated with cetuximab (50 µg/mL) or control-treated with DMSO for 24h (n = 3) and HER3 expression was 
measured by qPCR as described in the Materials and Methods section. Student’s t-test significance: *p < 0.05, **p < 0.01, ***p < 0.001. 
(D) LIM1215  and HCA7 cells were treated with GDC-0941 (1 µM) or (E) trametinib (0.1 µM) for different time points. Protein levels were 
detected by western blotting as described in the Materials and Methods section.
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Inhibition of HER3 activation through multi-
ErbB combination regimens
HER3 phosphorylation can be mediated by multiple 
kinases such as Src [36], MET [37] and FGFR2 [38] in 
addition to its family members EGFR and HER2. Since 
our RTK arrays did not reveal high phosphorylation 
levels of neither MET nor FGFR2 in LIM1215 cells after 
cetuximab treatment (Figure 1A), we hypothesized that 
HER3 is predominantly phosphorylated by EGFR or 
HER2, which has decreased levels of activation (Figure 1), 
but still can phosphorylate HER3 due to increased 
dimerization with it (Figure 3). Hence, we sought to 
identify whether combination strategies using EGFR and 
HER2 targeted drugs could inhibit the previously observed 
cetuximab-induced feedback activation of HER3. First, we 
evaluated whether monotherapy with the EGFR kinase 
inhibitor gefitinib and the reversible EGFR/HER2 kinase 
inhibitor lapatinib could prevent the cetuximab-induced 
activation of HER3 in LIM1215 cells. In exploratory 
experiments using CEER, treatment with gefitinib showed 
results in the same line as cetuximab treatment in terms 
of induction of heterodimer formation, HER3 protein 
levels and phosphorylation and elevation of HER3:PI3K 
p85 binding (Supplementary Figure S2B). However, 
treatment with he combined EGFR/HER2 kinase inhibitor 
lapatinib showed a blockage in the increase in HER3 
phosphorylation and HER3:PI3K p85 binding (Figure 
4A and Supplementary Figure S2A). It is thus interesting 
that even if lapatinib treatment increased NRG1 mRNA 
levels and HER3 mRNA and protein levels compared to 
control treatment (Figure 2A and 2B and Supplementary 
Figure S2A), it normalized both HER3 phosphorylation 
and associated HER3:PI3K p85 binding. This suggests 
that HER2-HER3 crosstalk is required to achieve 
feedback upregulation of HER3 together with receptor 
phosphorylation. The effect of lapatinib on preventing 
the increase in HER3 phosphorylation observed upon 
cetuximab treatment was further supported by a western 
blotting temporal analysis (Figure 4B). Additionally, 
while cetuximab treatment lead to a 5.4-fold induction 
of HER2:HER3 heterodimers, lapatinib treatment only 
showed a 1.7-fold increase (Figure 3A and Figure 4A). 
Moreover, both gefitinib and lapatinib treatments showed 
a decrease in ERK and AKT phosphorylation compared 
to control treatment. Concerning ERK, a 4.7-fold and a 
5.5-fold decrease were observed respectively and for 
AKT a 2.4-fold and a 7.1-fold, suggesting that lapatinib 
inhibits ERK and AKT phosphorylation more potently 
than gefitinib (Supplementary Figure S2A and S2B).
Figure 3: Cetuximab results in increased heterodimer formation and HER3:PI3K binding. (A) LIM1215 cells were treated 
with cetuximab (50 µg/mL) for 24h and heterodimer formation between EGFR family members as well as both total and phosphorylated 
levels of EGFR were assessed by CEER by Prometheus Laboratories Inc. San Diego, CA (USA). The results are expressed as mean 
± SEM. A total of 6 microarray spots were analyzed for each sample. CU: computed unit. (B) Dimerization of HER2:HER3 proteins 
induced by cetuximab demonstrated by FRET/FLIM analysis. LIM1215 cells were seeded on glass coverslips. 2 days later media was 
changed to serum free for 24h prior treatment with cetuximab (100 nM, 4h). Cells were fixed and stained with anti-HER3-IgG-Alexa546 
(donor) and anti-HER2-IgG-Cy5 (acceptor) antibodies. Lifetime images acquired on custom build microscope and analyzed with 
TRI2 software [44]. The difference between untreated and treated cells is statistically significant (data are expressed as means ± SEM, 
*−P < 0.01, Student’s t-test) (n = 4). 
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Next, using the same rationale, we tested different 
drug combinations targeting EGFR and HER2. We treated 
LIM1215 cells combining cetuximab with the monoclonal 
antibody HER2 inhibitor trastuzumab and cetuximab 
with the HER2 dimerization inhibitor pertuzumab to find 
drug combinations that could alter the cetuximab-induced 
feedback activation of HER3. Co-treatment with cetuximab 
and trastuzumab could partially inhibit EGFR:HER2 dimer 
formation (Figure 4C). In contrast, we observed no decrease 
in HER3 phosphorylation, potentially due to the remaining 
EGFR:HER3 dimer levels that we observe in this context 
(Supplementary Figure S2C and Figure 4C). Co-treatment 
with cetuximab and pertuzumab did not inhibit heterodimer 
formation nor prevented HER3 phosphorylation 
(Figure 4D and Supplementary Figure S2D). Both 
co-treatments showed an induction of total levels of 
HER3 compared to baseline conditions (Supplementary 
Figure S2C and S2D). In terms of ERK and AKT, both 
co-treatment with cetuximab and trastuzumab and co-
treatment with cetuximab and pertuzumab reduced the 
phosphorylated levels of both molecules compared to 
control treatments (Supplementary Figure S2C and S2D). 
The reduction on AKT phosphorylation upon these two co-
treatments and upon gefitinib and lapatinib monotherapy, 
together with the induction of total levels of HER3 in all 
these treatments, is in line with our previous results where 
we showed that feedback activation of HER3 occurs, at 
least partly, through AKT inhibition. 
Taken together, we showed that lapatinib is able 
to block the increase in cetuximab-induced HER3 
phosphorylation, suggesting that HER2 facilitates HER3 
signaling.
Figure 4: Time-dependent increase in HER3 phosphorylation does not occur upon lapatinib treatment. LIM1215 
cells were treated with (A) lapatinib (1 µM), (C) cetuximab (50 µg/mL) and trastuzumab (20 µg/mL) or (D) cetuximab (50 µg/mL) and 
pertuzumab (10 µg/mL) for 24h and heterodimer formation between EGFR family members as well as both total and phosphorylated levels 
of EGFR were assessed by CEER by Prometheus Laboratories Inc. San Diego, CA (USA). The results are expressed as mean ± SEM.  A 
total of 6 microarray spots were analyzed for each sample. CU: computed unit. (B) LIM1215 and HCA7 cells were treated with lapatinib 
(1 µM) for different time points. Protein levels were detected by western blotting as described in the Materials and Methods section.
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HER3 inhibition increases the sensitivity of 
cancer cells to ErbB inhibitors
We observed that, after different EGFR and 
HER2 inhibition strategies, upregulation of HER3 and 
incomplete inhibition of AKT and ERK occurred (Figure 
1, Supplementary Figures S1 and S2). Therefore, we 
hypothesized that inhibition of HER3 could lead to an 
increased sensitivity to ErbB inhibitors. To test this, 
we utilized a shRNA-based genetic inhibition strategy 
and assessed monotherapy and combination strategies 
of EGFR and HER2 inhibitors in LIM1215 cells, based 
on our results showing the ability of lapatinib to block 
the increase in HER3 phosphorylation (Figure 4B and 
Supplementary Figure S2A). Notably, treatment of 
cetuximab combined with lapatinib was already more 
potent than cetuximab treatment alone and knockdown of 
HER3 could additionally sensitize LIM1215 cells to this 
combination (Figure 5B). Due to the observed ability of 
lapatinib to prevent an increase in HER3 phosphorylation 
(Figure 4B and Supplementary Figure S2A), we tested an 
additional EGFR/HER2 inhibitor, namely the irreversible 
covalent EGFR/HER2 tyrosine kinase inhibitor afatinib. 
The effect observed upon lapatinib treatment was different 
for afatinib, which resulted in a more potent inhibition 
and which remains unexplained. Indeed, treatment with 
afatinib resulted in a decrease in cell viability compared 
to lapatinib, while these cells were not further sensitized 
to afatinib by knockdown of HER3. 
Next, we wanted to provide further evidence on the 
need of HER2-HER3 crosstalk for the feedback HER3 
phosphorylation presented before by altering the activity 
of HER3. To this end, we activated HER3 in LIM1215 
cells through exposure to the exogenous HER3 ligand 
NRG1 and tested short-term treatment combinations 
with EGFR and HER2 inhibitors. As expected, HER3, 
AKT and ERK phosphorylation were potently induced in 
the presence of NRG1 (Figure 5C). Cetuximab was not 
able to inhibit this induction of HER3, AKT and ERK 
phosphorylation. Similarly, resistance to cetuximab was 
induced by treatment of these cells with NRG1 when 
measured in a long-term proliferation assay (Figure 5D). 
However, the observed NRG1-induced HER3, AKT and 
ERK phosphorylation could be prevented by co-treatment 
of cetuximab with lapatinib or afatinib (Figure 5C). This 
was confirmed in HCA7 cells (Figure 5C). Additionally, 
co-treatment with cetuximab and lapatinib was found 
capable to revert the NRG1-induced resistance to 
cetuximab in LIM1215 cells in a long-term proliferation 
assay (Figure 5D). Together, these data support the HER2-
HER3 crosstalk required for endogenous feedback HER3 
phosphorylation upon cetuximab treatment and suggests 
that co-treatment with cetuximab and lapatinib may 
warrant further investigation in order to prevent therapy 
resistance.
DISCUSSION
Cetuximab is approved for the treatment of 
metastatic colorectal cancer but its response rate in KRAS, 
BRAF, NRAS and PIK3CA exon 20 quadruple wild-type 
tumors accounts for only 41%, leaving a high percentage 
of non-responders [12]. Furthermore, both innate and 
acquired resistance mechanisms previously described in 
this manuscript limit cetuximab’s effectiveness [13–19]. 
Moreover, there is evidence of resistance through feedback 
loops in the context of different targeted drugs including 
BRAF, PI3K/AKT and MEK inhibitors [20–23]. These 
evidences point towards a rather low success rate of 
monotherapy targeted anticancer agents for the treatment 
of colorectal cancer. 
Here, we showed the occurrence of a cetuximab-
induced time-dependant increase in total HER3 protein 
levels and HER3 phosphorylation in KRAS and BRAF 
wild-type cells (Figure 1 and Supplementary Figure S1). 
Time-dependant feedback HER3 activation after EGFR 
inhibition has also been proposed in the context of 
breast cancer, although these breast cancer cells already 
presented with HER3 phosphorylation at baseline [39]. 
Moreover, we also showed that mRNA upregulation 
of HER3 occurred within 24h of cetuximab, gefitinib 
and lapatinib treatment (Figure 2A), suggesting that 
HER3 expression is negatively regulated by signaling 
downstream of EGFR. AKT-regulated feedback induction 
of RTKs through relief of negative feedback signaling has 
been previously shown [26, 27]. Furthermore, it has been 
described that the PI3K/AKT pathway is mainly mediated 
through HER3 [40, 41]. Using an AKT constitutively 
active mutant construct, we showed that the transcriptional 
changes in HER3 induced by cetuximab could be 
prevented (Figure 2C). This suggests that feedback 
activation of HER3 occurs, at least partly, through AKT 
inhibition, although we were not able to elucidate through 
which exact mechanism this occurs. This is in line with 
previous reports in breast cancer cells where myristoylated 
AKT prevents the escape of HER3 to EGFR inhibition 
with gefitinib treatment [39]. Concomitant to this, we 
observed an induction of HER2:HER3 heterodimers 
(Figure 3), suggesting that HER2 allows the kinase-
impaired HER3 receptor to gain signaling capacity.
In agreement with the results presented in this 
manuscript, increased HER3 abundance and ErbB 
heterodimers after EGFR-targeted therapy has been 
shown for breast cancer patients [32]. Interestingly, we 
observed that lapatinib treatment normalized both HER3 
phosphorylation and associated HER3:PI3K p85 binding 
(Figure 4A, Figure 4B and Supplementary Figure S2A). 
Furthermore, the induction of HER2:HER3 dimers was 
three times lower upon lapatinib treatment compared 
to cetuximab (1.7-fold induction vs. 5.4-fold induction) 
(Figures 4A and 3A). Hence, we suggest that HER2 
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induces, at least partly, the phosphorylation of cetuximab-
induced upregulated HER3, and inhibiting HER2 with 
lapatinib, coupled with EGFR inhibition, limits this effect.
Due to the cetuximab-induced feedback activation 
of HER3, we hypothesized that sensitivity to EGFR 
inhibitors could be improved by inhibiting HER3. Here, 
we showed that cetuximab combined with lapatinib was 
able to decrease cell viability upon HER3 knockdown 
compared to prior to HER3 inhibition (Figure 5B). 
However, we were not able to elucidate how these events 
lead to cetuximab resistance in terms of downstream 
molecules, signaling pathways and biological processes 
involved. Nevertheless, we showed that combinatorial 
drug therapy with cetuximab and lapatinib was able to 
reduce cell viability compared to cetuximab treatment 
alone (Figure 5B) and it also reverted NRG1-induced 
resistance to cetuximab in a long-term proliferation assay 
(Figure 5D).  Hence, we believe that this combinatorial 
drug therapy may be worth to investigate as a potential 
treatment strategy in order to prevent cetuximab resistance. 
Interestingly, cetuximab plus lapatinib combination has 
been assessed in quadruple negative colorectal cancer 
patient-derived xenografts [42]. In 5 out of 21 cases, 
this combination caused tumor regression compared to 
cetuximab treatment alone, supporting the rationale of 
this drug combination. Remarkably, in 6 out of the 16 
cases where cetuximab plus lapatinib was not superior 
to cetuximab alone, overexpression of the IGF1R ligand 
IGF2 was found. This is compatible with the RTK array 
data in our cell lines (Figure 1A) where we do not observe 
IGF1R phosphorylation induction.
Together, we showed feedback HER3 activation 
upon cetuximab treatment in KRAS and BRAF colon cancer 
cells together with induction of HER2:HER3 heterodimers, 
which could potentially result in cetuximab resistance in 
colorectal cancer patients. As a matter of fact, HER3-
mediated resistance to EGFR inhibition with gefitinib has 
been described in lung cancer cells [37]. Interestingly, 
Figure 5: HER3 knockdown sensitizes LIM1215 cells to EGFR inhibitors and co-treatment of cetuximab with lapatinib 
prevents HER3 activation and resistance through NRG1 stimulation. (A) Validation of HER3 knockdown in LIM1215 cells. 
HER3 expression was measured by qPCR as described in the Materials and Methods section. (B) LIM1215 cell viability measurement 
upon shRNA-based genetic inhibition of HER3 (shHER3) or control (shGFP) after 72h treatment with different drugs as described: control-
treatment with DMSO, cetuximab (50 µg/mL), lapatinib (1 µM), afatinib (1 µM) and trastuzumab (20 µg/mL). Data are expressed as 
mean ± standard deviation. (C) LIM1215 and HCA7 cells were treated as described with the following drugs: control-treated with DMSO, 
cetuximab (50 µg/mL), lapatinib (1 µM), trastuzumab (20 µg/mL) or afatinib (1 µM). Cells were treated for 2h in the presence or absence of 
10 min NRG1 stimulation (50 ng/mL). Protein levels were detected by western blotting as described in the Materials and Methods section. 
(D) LIM1215 10-day colony formation upon treatment with different drug combinations as described and in the presence or absence of 
NRG1 (50 ng/mL). 
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results from the CALGB 80203 study, where metastatic 
colorectal cancer patients were randomly allocated to 
receive either leucovorin/fluorouracil/irinotecan (FOLFIRI) 
or leucovorin/fluorouracil/oxaliplatin (FOLFOX) with or 
without cetuximab, showed that KRAS wild-type patients 
with high levels of HER3 did not benefit from cetuximab 
and were associated with therapy resistance [43]. Overall, 
our results suggest that after cetuximab treatment not only 
internalization of EGFR occurs, but also other events 
might take place, such as feedback activation of HER3 or 
formation of new ErbB dimers. Dynamic monitoring of 
changes in dimer formation might be used to predict on 
treatment increased efficacy of drug combination strategies. 
The data presented in this manuscript adds to the body 
of evidence that feedback mechanisms in intermediate 
cetuximab-sensitve colon cancer cells, which represent 
most colorectal cancer patients, would dictate the transient 
and not profound response to cetuximab monotherapy. 
MATERIALS AND METHODS
Cell lines and reagents
LIM1215, HCA7 and HEK-293T cell lines were 
cultured in DMEM/F-12 + L-Glutamine + 15 mM HEPES 
(Gibco) supplemented with 10% fetal bovine serum (FBS) 
(HyClone) and 1% penicillin/streptomycin (Gibco) at 
37ºC with 5% CO2. LIM1215 cells were obtained from 
the Ludwig Institute for Cancer Research, New York, NY, 
USA and HCA7 and HEK-293T cells were obtained from 
the American Type Culture Collection (ATCC).
Cetuximab (Erbitux®) was purchased from Merck 
Serono, lapatinib (Tykerb/Tyverb®) from GlaxoSmithKline, 
and trastuzumab (Herceptin®) and pertuzumab (Perjeta®) 
from Roche. Gefitinib (ZD1839), GDC-0941, trametinib 
(GSK1120212) and afatinib (BIBW2992) were purchased 
from Selleck Chemicals. NRG1 was purchased from 
Peprotech.
RTK array analysis
Cells were seeded in 10 cm plates (Sarstedt) 
(3,000,000 cells/plate) and grown 24h before starving them 
overnight. Cells were treated with cetuximab or control-
treated as indicated. The medium was replaced by 10% 
FBS supplemented medium 10 min before cell harvesting. 
Cells were lysed, samples prepared and immunoblotting 
performed according to protocol Proteome Profiler 
Human Phospho-RTK Array Kit (R&D Systems). Array 
quantification was performed with ImageJ.
Western blotting analysis
Cells were seeded in 10 cm plates (Sarstedt) 
(3,000,000 cells/plate) and treated for different time points 
in the presence or absence of drugs as indicated. Cells were 
harvested, washed with ice-cold phosphate buffered saline 
(PBS) (Gibco) and lysed with NP-40 buffer supplemented 
with phosphatase inhibitors (Sigma-Aldrich) and 
protease inhibitor (Roche). Protein concentration was 
measured by bicinchoninic acid assay (BCA) (Thermo 
Scientific). Lysates were loaded and separated in sodium 
dodecyl sulfate (SDS) polyacrylamide gels 4–12% (Life 
Technologies) and transferred to nitrocellulose membranes 
(Life Technologies) using iBlot2 Dry Blotting System 
(Life Technologies). Membranes were blocked with 5% 
bovine serum albumin (BSA) (Sigma-Aldrich) in tris-
buffered saline and Tween 20 (TBS-T) (50 mM Tris, 
150 mM NaCl, 0.1% Tween 20, pH 7.6) and incubated 
overnight at 4ºC with the following primary antibodies 
diluted in 5% BSA in TBS-T: P-HER3 (Y1289) (D1B5) 
Rabbit mAb, ErbB-3 (C-17) sc-285 Lot #H2712 rabbit 
polyclonal IgG, P-AKT (Ser473) (193H12) Rabbit mAb, 
AKT Rabbit Ab, P-ERK1/2 (Thr202/Tyr204) Rabbit Ab, 
ERK1/2 (137F5) Rabbit mAb, GAPDH (14C10) Rabbit 
mAb. All primary antibodies were purchased from Cell 
Signaling and were used in a 1:1000 dilution except for 
the ErbB-3 (C-17) sc-285 Lot #H2712 rabbit polyclonal 
IgG antibody that was purchased from Santa Cruz 
Biotechnology. Membranes were washed with TBS-T, 
incubated with Goat anti-Rabbit secondary antibody 
(Dako) 1:5000 in 5% BSA and washed again with TBS-T. 
Protein signal was detected using chemiluminescent 
Luminata Forte Western HRP Substrate (Millipore) 
by exposing Amersham Hyperfilm ECL films (GE 
Healthccare) to the processor CURIX 60 (AGFA). Western 
blotting quantification was performed with ImageJ.
Collaborative Enzyme Enhanced Reactive-
immunoassay (CEER)
Cell lysates were prepared according to the 
manufacturer’s protocol and were sent to Prometheus 
Laboratories Inc. (San Diego, CA, USA) for further analysis. 
Förster resonance energy transfer (FRET)/
fluorescence lifetime imaging microscopy 
(FLIM)
Anti-HER3 (B9A11) was purchased from 
Monogram Biosciences and anti-HER2 (e2-4001+3B5) 
was purchased from Thermo Scientific and directly 
labelled according to the manufacturer’s protocol with 
Alexa546 (X546) and Cy5, respectively. 
Imaging and analysis of HER2:HER3 dimer by 
FRET/FLIM was described previously [44].
RNA extraction, reverse transcription and 
quantitative PCR (qPCR)
Cells were seeded in 6-well plates (Cellstar) 
(400,000 cells/well) and treated in the presence or absence 
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of drugs as indicated. RNA extraction was performed 
according to protocol MasterPure RNA Purification Kit 
(Illumina). Reverse transcription was performed with 
SuperScript II Reverse Transcriptase (Life Technologies) 
according to the manufacturer’s instructions. Gene 
expression was analyzed using quantitative polymerase 
chain reaction (qPCR) in 7500 Real Time PCR System 
(Applied Biosystems). Target gene expression was 
calculated relative to a reference gene that served as 
endogenous control (GAPDH) using the comparative Ct 
method. Each sample was analyzed in duplicate and the 
mean of all biological replicates was expressed as the 
result together with the standard deviation. The following 
primers were used: HER3 forward (5′-GGG GAG TCT 
TGC CAG GAG-3′), HER3 reverse (5′-CAT TGG GTG 
TAG AGA GAC TGG AC-3′), NRG1  forward (5′- TGG 
CTG ACA GCA GGA CTA AC-3′), NRG1 reverse (5′- 
CTG GCC TGG ATT TCT TC-3′), GAPDH forward 
(5′-AAG GTG AAG GTC GGA GTC AAC-3′), GAPDH 
reverse (5′-GAG TTA AAA GCA GCC CTG GTG-3′). 
Myristoylated AKT transfection
Cells were seeded in 6-well plates (Cellstar) 
(1,000,000 cells/well) and transfected with 2 µg 901 
pLNCX-myr-HA-AKT plasmid DNA (Addgene plasmid # 
9005) or 2 µg pmaxGFP® vector using the Nucleofector® 
technology (Lonza). The plasmid encoding myristoylated 
AKT was provided by William Sellers. 
shHER3 viral transduction
pLKO.1-shHER3 (RHS3979-9630819) and pLKO.1-
shGFP were purchased from Open Biosystems. Virus were 
produced in HEK-293T cells with FuGENE® 6 Transfection 
Reagent (Promega) and transduced into LIM1215 cells. 
Infected cells were selected with 2 µg/mL puromycin 
treatment (Santa Cruz Biotechnology) for 2 days.  
Cell viability analysis
Cells were seeded in 96-well plates (Becton 
Dickinson) (6,000 cells/well), treated in triplicates in the 
presence or absence of drugs as indicated and cultured for 
72h. Cell viability was measured according to protocol 
CellTiter-Glo Luminescent Cell Viability Assay (Promega) 
using the machine VICTOR X3 2030 Multilabel Plate 
Reader (Perkin Elmer) and expressed as the mean of the 
triplicates relative to the non-treated control together with 
the standard deviation. 
Colony formation analysis
Cells were seeded in 24-well plates (Cellstar) (5,000 
cells/well), treated in the presence or absence of drugs as 
indicated and cultured for 10 days refreshing the medium 
and drugs every two days. Cells were stained with crystal 
violet solution (Sigma-Aldrich) and washed with PBS.
Statistical analysis
Unpaired Student’s t-test was used to compare 
means of two groups.
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